Drug repositioning is a promising drug development technique to identify new indications for existing drugs. However, existing computational models only make use of lower-order biological information at the level of individual drugs, diseases and their associations, but few of them can take into account higher-order connectivity patterns presented in biological heterogeneous information networks (HINs). In this work, we propose a novel graph representation learning model, namely FuHLDR, for drug repositioning by fusing higher and lower-order biological information. Specifically, given a HIN, FuHLDR first learns the representations of drugs and diseases at a lower-order level by considering their biological attributes and drug-disease associations (DDAs) through a graph convolutional network model. Then, a meta-path-based strategy is designed to obtain their higher-order representations involving the associations among drugs, proteins and diseases. Their integrated representations are thus determined by fusing higher and lower-order representations, and finally a Random Vector Functional Link Network is employed by FuHLDR to identify novel DDAs. Experimental results on two benchmark datasets demonstrate that FuHLDR performs better than several state-of-the-art drug repositioning models. Furthermore, our case studies on Alzheimer's disease and Breast neoplasms indicate that the rich higher-order biological information gains new insight into drug repositioning with improved accuracy.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: